Media headlines about MEI Pharma (NASDAQ:MEIP) have been trending positive on Saturday, according to Alpha One. The research group, a unit of Accern, scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.31 on Alpha One’s scale. Alpha One also gave media stories about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have effected Alpha One Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for MEI Pharma (NASDAQ:MEIP)

Several equities research analysts recently weighed in on MEIP shares. Oppenheimer Holdings, Inc. set a $7.00 price objective on shares of MEI Pharma and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “strong-buy” rating and set a $1.75 price objective on the stock in a research note on Tuesday, May 9th. Finally, Cann reiterated a “buy” rating and set a $6.50 price objective on shares of MEI Pharma in a research note on Monday, June 5th.

Shares of MEI Pharma (NASDAQ MEIP) opened at 2.01 on Friday. The firm has a market cap of $73.91 million, a price-to-earnings ratio of 59.12 and a beta of 1.29. MEI Pharma has a 1-year low of $1.25 and a 1-year high of $2.35. The company’s 50-day moving average is $1.80 and its 200 day moving average is $1.63.

MEI Pharma (NASDAQ:MEIP) last issued its earnings results on Thursday, May 4th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $4.51 million for the quarter, compared to analyst estimates of $5 million. On average, equities research analysts expect that MEI Pharma will post $0.02 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “MEI Pharma (MEIP) Receiving Positive News Coverage, AlphaOne Reports” was originally reported by Financial Market News and is owned by of Financial Market News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at

About MEI Pharma

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with's FREE daily email newsletter.